MOH (Palestine)

The Palestine Ministry of Health (MoH, Wizārat al-Siḥḥa al-Filasṭīniyya) is the national regulator for human medicines, biologicals and vaccines, medical devices, in vitro diagnostics, cosmetics, dietary supplements, pharmacy practice, and controlled substances. Regulatory operations are led by the Pharmaceutical General Administration (PGA) and supported by the Central Public Health Laboratory (CPHL) for quality control testing and the Palestinian National Pharmacovigilance Centre for safety monitoring.

Headquarters functions are centered in Ramallah for the West Bank and East Jerusalem. Since 2007, a parallel MoH structure in Gaza has operated semi-independently, resulting in duplicated touchpoints for registration and import control. This duality is an operational fact underpinning dossier strategy, import routing, and post-market oversight for any sponsor seeking Palestinian market access.

Day-to-day regulatory practice reflects the constraints of the Paris Protocol customs union, Israeli import licensing controls, and humanitarian program dominance in certain therapeutic areas. UNRWA’s network of about 140 primary healthcare centers and WHO, UNICEF, UNFPA, and ICRC programs significantly influence procurement choices, product specifications, and delivery timelines.

Regional collaboration is pragmatic. Palestine MoH participates in WHO EMRO activities and WHO’s Programme for International Drug Monitoring, and maintains working ties with peer authorities in Jordan and Egypt. For specific cross-border matters and controls, sponsors often see process interfaces with the Israel MoH, particularly for customs, cold-chain, and entry-point coordination.

Palestine MoH authority flows primarily from the Palestinian Public Health Law No. 20 of 2004, Pharmacy Practice Law No. 21 of 2017, the Drug Registration Decision No. 1 of 2013, and the Narcotics and Psychotropics Law No. 7 of 1955 as amended. Council of Ministers decisions, PGA administrative decisions, and MoH guidance circulars further operationalize requirements for dossier content, testing, labelling, import permits, and vigilance.

While these instruments are domestic, regulatory practice often relies on recognized international standards. For quality systems and GMP, Palestine MoH aligns to WHO and PIC/S concepts, accepts GMP certificates from trusted authorities, and references pharmacopoeial standards. For devices and IVDs, ISO 13485-based quality evidence and recognized international technical documentation are generally expected.

Chemistry, manufacturing, and controls requirements typically mirror the ICH CTD, with impurity control and specification setting guided by ICH principles. Clinical and nonclinical summaries may leverage reliance on approvals by trusted reference agencies. Stability expectations usually follow ICH climatic zone guidance tailored to local conditions.

Sponsors should be prepared to submit authenticated Arabic translations of core labelling and key administrative documents, while maintaining English technical appendices for complex content. Controlled substance dossiers additionally require narcotics oversight documentation, quota management, and storage controls aligned to Palestinian law.

Reference materials that MoH commonly accepts include WHO GMP guidance and ICH impurity standards. See WHO GMP TRS 1044 (2022) and ICH Q3A (impurities in drug substance) for typical technical anchors in CMC sections and release specifications.

The framework covers Palestinian and foreign manufacturers, marketing authorization holders, importers and distributors, hospital and community pharmacies, humanitarian organizations, and third-party logistics providers handling health products. Any product intended for human use that makes medicinal or preventive claims is likely in scope unless expressly exempted. Cosmetics and dietary supplements are regulated with tailored dossiers, quality documentation, and labelling rules, but are still subject to import permitting and market surveillance.

Medical devices and IVDs follow risk-based categories derived from international practice, with technical documentation, clinical or performance evaluation commensurate with class, and quality system evidence based on ISO 13485. Local authorized representatives are typically required for foreign manufacturers, with clear responsibility for vigilance and recalls.

Arabic labelling is the rule for retail products, with English commonly accepted for professional-use components and complex device instructions, provided Arabic overlays or inserts address critical safety and use information. Hospital-only products can maintain English primary labels when accompanied by an Arabic leaflet and when permitted by MoH.

Controlled substances are subject to additional licensing, quotas, and storage-security controls, including chain-of-custody documentation and inventory reconciliation. Pharmacy practice, dispensing controls, and prescription requirements are enforced under Pharmacy Practice Law and narcotics regulations.

• Domestic manufacturers: facility licensing, GMP oversight, and product registration are managed by PGA with CPHL support.
• Foreign manufacturers: require a local representative responsible for dossiers, samples, vigilance, and recalls.
• Importers and distributors: must hold import and wholesale licenses, approved storage sites, and cold-chain capabilities where applicable.
• Humanitarian operators: use dedicated registration or waivers where available, but still undergo quality and labelling scrutiny.
• Pharmacies and hospitals: subject to dispensing, storage, and record-keeping requirements, including controlled-substance safeguards.
• Device/IVD sponsors: follow risk-based classification and maintain ISO 13485 evidence; class dictates documentation depth per medical device classification.

All actors should align vigilance systems with Palestine’s National Pharmacovigilance Centre expectations on case intake, evaluation, and reporting. Sponsors remain responsible for timely corrective and preventive actions when safety signals arise, regardless of whether products enter via commercial or humanitarian channels. See pharmacovigilance for baseline concepts that apply after Palestinian registration.

For medicines and vaccines, the Palestine MoH commonly accepts CTD-structured dossiers. Core elements include administrative data, legalized manufacturing authorizations, GMP certificates from recognized authorities, product quality review or batch summary reports, stability data suitable for local climate, validated analytical methods, and labelling in Arabic. Clinical and nonclinical summaries can leverage reliance on approvals by trusted agencies, with unredacted assessment reports strengthening the case.

For devices and IVDs, technical files should demonstrate safety and performance with class-appropriate clinical or performance evidence. ISO 13485 certification, risk management files, biocompatibility or shelf-life studies, software validation where applicable, and conformity with recognized standards are central. Conformity evidence from reputable markets supports reliance; however, local language materials and post-market arrangements must still meet Palestinian rules.

CPHL commonly requires product samples and reference standards for confirmatory testing during registration and periodically post-approval. Lot release for certain vaccines and biologics may involve additional documentation and cold-chain verification. Timelines are sensitive to sample logistics and import permissions for trial batches or registration samples.

The West Bank–Gaza operational split means sponsors often prepare parallel cover letters, fee proofs, and logistics plans even when the core technical file is shared. Labeling variants and distribution maps are assessed with geography-specific endpoints in mind. Renewals and variations follow the same split, with pharmacovigilance commitments carried through both channels.

Importation into Palestinian territories occurs within the Paris Protocol customs union framework. Israeli authorities control customs entries and many health-product import licenses, even when the Palestinian MoH is the registering authority. In practice, sponsors need both Palestinian approvals and Israeli entry clearances, with particular attention to cold-chain shipments, hazardous materials declarations, and controlled-substance quotas.

For West Bank entries, the Allenby/King Hussein Bridge is the predominant route, whereas Gaza-bound consignments frequently depend on Rafah or designated Israeli-controlled crossings subject to security openings. Transit times are volatile; validated shipping configurations, temperature-monitoring devices, and contingency stock strategies are essential to preserve product integrity.

Wholesale distribution and storage sites must be licensed, mapped, and audited for conditions, security, pest control, and temperature performance. For vaccines and biologics, continuous temperature monitoring and excursion management are standard expectations. Documentation, including certificates of analysis and batch release documentation, must accompany consignments to facilitate batch verification and CPHL sampling.

Humanitarian consignments can access expedited or exceptional procedures, but they remain subject to verification and post-market scrutiny. Sponsors should align commercial and humanitarian documentation standards to avoid split-quality systems and to simplify vigilance and recall execution.

• Palestinian MoH registration certificate or waiver for humanitarian supplies.
• Import license or prior notice as applicable, with Israeli entry authorization where required.
• Certificates of analysis, batch release documentation, and packing lists with lot-level traceability.
• Cold-chain evidence (calibrated monitors, temperature logs, validated shippers) for temperature-sensitive products.
• Arabic labelling or approved overlays and leaflets; hospital-only exceptions documented.
• Controlled-substance permits and inventory reconciliation plans when applicable.

Sponsors should align import planning to recognized best practices on importation and distribution controls. See Annex 21: importation for EU importation expectations that are widely mirrored, and the guide on EU GDP readiness for distribution system controls relevant to Palestinian wholesale licensing.

Palestine MoH accepts GMP evidence from trusted authorities and WHO-aligned audits. Domestic manufacturers undergo licensing and inspections aligned to WHO GMP concepts, including personnel qualifications, validated processes, calibrated equipment, and controlled documentation. Foreign manufacturers typically submit valid GMP certificates and recent inspection summaries alongside the dossier.

CPHL provides independent quality control testing at registration and through market surveillance. Sponsors should be prepared to submit reference standards, method validation summaries, and system suitability criteria to support confirmatory testing. For biologics and vaccines, potency, sterility, and identity testing may be supplemented by lot release documents from the manufacturer’s reference authority.

Process validation, cleaning validation, and stability programs should align to ICH and WHO expectations. For sterile products, aseptic process controls, environmental monitoring, and media fills are scrutinized. Utilities, especially water systems, require qualification and routine monitoring appropriate to dosage form and use.

Device and IVD sponsors should maintain ISO 13485 certification, validated sterilization or shelf-life studies, and robust supplier control. Software-containing devices need verification and validation traceability, with cybersecurity considerations where networked functions are present and risk-relevant.

Reference frameworks commonly used by sponsors include WHO GMP and platform controls for critical utilities. See WHO GMP TRS 1044 (2022) for contemporary interpretations, and align water system design and monitoring to pharmaceutical water systems practices.

The Palestinian National Pharmacovigilance Centre participates in WHO’s Programme for International Drug Monitoring, integrating local adverse event data into global signal detection. Marketing authorization holders must maintain systems for intake, evaluation, coding, and timely reporting of individual case safety reports, periodic safety updates where required, and risk management activities.

For medical devices and IVDs, serious incidents and field safety corrective actions must be reported without delay, with field safety notices issued to users and distributors in Arabic. Traceability to lot or serial number is essential for targeted corrective actions, and distributors are expected to support outreach and remediation rapidly.

Market surveillance includes CPHL sampling, inspection of wholesalers and pharmacies, and verification of storage conditions. Suspected falsified products trigger targeted investigations and coordination with neighboring authorities when cross-border movement is suspected. Humanitarian channels are not exempt from recall and corrective action obligations.

Sponsors should harmonize internal global safety processes with Palestinian reporting timelines and formats. Establish clear interfaces with local representatives and distributors to ensure robust complaint handling, case triage, and escalation that meet MoH expectations.

See core concepts under pharmacovigilance and post-market surveillance for structuring safety systems, recall readiness, and signal evaluation plans applicable to the Palestinian market.

In practice, Palestine MoH leverages reliance on decisions and certificates from trusted reference authorities, especially where local capacity is constrained or where urgent access is needed. Jordan and Egypt are frequent comparators given logistics, therapeutic alignment, and historical trade flows. Unredacted approval packages, GMP certificates, and batch release documents from these markets can accelerate evaluation.

WHO prequalification status is influential in tenders and procurement decisions, particularly for vaccines, certain antimicrobials, and reproductive health commodities. Humanitarian procurements by UNRWA, WHO, UNICEF, and partners follow donor and UN procurement rules while still liaising with Palestinian MoH for entry, distribution, and post-market oversight. Sponsors supplying both commercial and humanitarian channels should align quality and labelling to avoid dual standards.

Where Israeli-controlled entries or security rules intersect with health-product logistics, documentation must satisfy both Palestinian registration and entry requirements managed by Israeli authorities. For cold-chain and hazardous consignments, this typically includes enhanced manifesting, route plans, and temperature-control evidence.

Manufacturers targeting Palestine often stage rollouts after securing approvals in neighboring jurisdictions. Mapping the order of submissions to Jordan, Egypt, and Palestine can reduce rework, synchronize artwork approvals, and anticipate CPHL testing needs. Aligning standards such as ISO 13485 for devices and WHO GMP for medicines across the region simplifies audits and supplier qualification.

For strategic dossier planning, cross-reference reliance sources and procurement levers. See WHO prequalification for recognized pathways that speed evaluation, and study comparator expectations in Jordan JFDA to model content and format choices that resonate with Palestinian reviewers.

Operational missteps in Palestine typically trace to underestimating the West Bank–Gaza split, documentation formalities, and Paris Protocol constraints. Sponsors that assume a single registration or import permit will cover both geographies often face delays at the first shipment. Build your program around parallel submissions and explicit logistics plans from the outset.

Another recurring issue is incomplete Arabic labelling or failing to provide bilingual critical safety information for professional-use products. Even where English is accepted in hospitals, Arabic inserts or overlays are commonly required. Artwork proofs should be reviewed against current MoH circulars to avoid relabeling.

Reliance without documentation is also a trap. Citing a foreign approval carries weight only when supported by authentic certificates, unredacted assessment reports where available, and up-to-date GMP evidence. For biologics, batch release alignment and cold-chain justification must be explicit.

Finally, CPHL testing logistics are frequently underestimated. Reference standards, validated methods, and sample volumes must be shipped with the same care as commercial lots, including temperature and security controls where relevant. Missing details in method-transfer packages can stall release.

1. Assuming West Bank approvals or permits automatically apply in Gaza, or vice versa.
2. Submitting English-only labels without Arabic overlays or inserts when required.
3. Relying on foreign approvals without authentic certificates or assessment documentation.
4. Neglecting temperature-control validation and excursion protocols for border delays.
5. Omitting reference standards or method-transfer detail for CPHL confirmatory testing.
6. Sequencing import permits after dispatch rather than before pickup and export clearance.

Palestinian market access hinges on disciplined document control, bilingual labelling, reliance documentation, verified cold-chain logistics, and robust vigilance. V5 Ultimate standardizes these workflows across West Bank and Gaza tracks so sponsors can run parallel submissions, batch testing, and import-permit sequencing without losing control of versions and timelines.

Regulatory and quality documents live in controlled libraries with approval workflows, audit trails, and scheduled reviews. Dossier assemblies capture reliance evidence from reference markets, while analytics flag gaps in GMP certificates, stability commitments, or CPHL method-transfer packages. For devices and IVDs, technical files and ISO 13485 records are organized with traceability to risk controls, usability outputs, and field actions.

On the logistics side, V5 connects batch records, release status, and import documentation to lot-level traceability. Temperature data from shippers and loggers can be attached to lots for rapid disposition at crossings. Integrated vigilance workflows streamline intake, medical review, bilingual communications, and recall execution with distributors and humanitarian partners.

Implementation accelerators include Palestine-specific templates for Arabic labelling overlays, import documentation checklists, and split-route shipment plans. Teams gain unified visibility and alerts across submissions, approvals, and shipments to keep both geographies moving together.